Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The explanation is here…..
https://www.ft.com/content/3256ba64-437f-4484-8012-1776194cfe23
I've been following my heart rather than my head with ONT as their kit is a big favourite among molecular biological colleagues. But this sudden drop from 275 to 225 without any news or explanation is disturbing. Is it just a consequence of the interest rate rises?
Several sells over £0.5m, even one of £1m over lunchtime at 210p somewhat alarming - no idea who.
So you do answer your own questions now then ,lol
I agree!
So at last we see the fruits of their hard work in the stock price that has a long way to climb. I did say the market needs to take these guys more seriously and so in my opinion the climb has begun. I just hope they climb before they’re bought out.
For me this is a good thing. Typically I get quite nervous when I am the last one on the boat. I hope we are in good position for the attention to shift to this company.
Am I missing something here? The market makers love this company and have a 350 price target, management is buying good quantities of their stock, the future looks of the industry looks strong and the company is well positioned/managed to grow into it, so why aren’t there more followers on here? .
you never know ,it could happen
Regardless of the cut, I'd be happy with 350p in the next 12m. Don't think we'll see it unless their business improves markedly or FED cuts rates
i was right with my prediction of 230p , nice
RBC cuts Oxford Nanopore price target to 350 (400) pence - 'outperform'
NIHR, Oxford Nanopore announce new health study
The study would involve using Oxford Nanopore's platform to sequence up to 22,000 samples to further research in the initial areas of psychiatric, common and rare disease.
Notice the word "initial" .
It would appear there is a great deal more to come !!!
next target 230p ,don't ask why
up 5% on what ?
I think CFO is being realistic.
Trading sideways @volcano.
looks like up and away here
So ONT has turned its largest (and only?) UAE customer into a distributor leading to a 50%+ reduction in revenue from that region? Based in 2022 results, this seems to me like a 50% discount to a client wrapped up as a distribution deal. I can't see any shareholder benefit in this move.
https://www.g42healthcare.ai/latest-update/g42-healthcare-signs-distribution-agreement-with-oxford-nanopore/
"Biogenix Labs – part of G42 Healthcare, became the first laboratory in the Middle East to conduct sequencing for Covid-19 surveillance and variant detection using Oxford Nanopore’s technology. "
that was me this morning ,
"we could see £2 today"
and here we are ,nice
Very informative webcast. Alot of positive developments coming and great set of results also sets the stall for a rise in share price from this ridiculous undervalued level.
Talk about the avenues they're exploring to increase its usage was very informative and sets a stake in the ground on where they need to aim to generate increased sales.
Aside, someone needs to pull the CFO aside and give him a pep talk on how to address investors. For god sake, talk up the results! Puts a negative tone on the COVID reduction in revs. That's pretty obvious, but his choice of words seem to suggest his 'glass half empty' mentality. If you don't believe in the company, p!ss off! Why describe it as a headwind? An 'expected decline' would suffice together with brief mention of the fact "the world has moved on from COVID and that its not really a meaningful contribution to their revs going forward...ANything is a bonus, but if it dropped to zero, we wouldn't care."
They reduced the loss to 91 million from 2021 167.6 million, they are not expected to make profit before 2027 and way they are managing and increasing revenue reducing loss that should give confidence going forward.
"but cash will be lower by 200M or more and valuation based on cash will be lower too."
Hmmm....This is a growth company.
So -50m cash flow from ops. 60m cash burn in total, down from FY21.
If they held their cash burn static for the next 4 full years (including FY26), they'd blow another 240m.
However, this doesn't really reflect the GM which is quite tidy, vs say Pacbio. They need to maintain that GM whilst scaling revs.
The EBITDA breakeven isn't cashflow from ops breakeven...the latter will take a little longer.
I didn't see anything meaningful regarding clinical deployment (That'll really bring in the bucks)
but cash will be lower by 200M or more and valuation based on cash will be lower too.
Good timing any bad news now would have been chaos, at least given us confidence now although the market is strange at the moment.